What You Need To Know About These 4 Falling Stocks

Horizon Pharma PLC (NASDAQ:HZNP) is off by 12.6% after the New York Times published an article detailing how Horizon’s Duexis costs $1,500-per-month, yet is just a combination of the generic equivalents of Pepcid and Motrin, which cost no more than $40 and $20-per-month, respectively. The Times article further states that Horizon has increased the price of Duexis by a factor of ten since late 2011 and has done similar things with Vimovo, a similar type of generic combination drug that the company acquired in 2013. Investors are selling the stock because New York Times articles are more likely to draw regulatory scrutiny. Any type of drug price ceiling could send Horizon Pharma’s 10.08 forward P/E higher.

WhiteWave Foods Co (NYSE:WWAV) is down by 7.8% after analysts at Goldman Sachs downgraded the company to ‘Sell’ from ‘Neutral’ and lowered their price target on the stock to $42 from $48, citing slowing organic growth. The analysts think the company will miss organic sales guidance growth by a percent or two over the next few years. The analysts also believe that slowing organic growth will lead to valuation compression.

Hedge funds were mixed on WhiteWave Foods Co (NYSE:WWAV) in the second quarter. Although the number of funds with long positions decreased to 30 from 33, the total value of their holdings in the stock increased to $809.99 million (representing 9.50% of the float), up from $741.67 million.

Disclosure: None